NCT04479579View on ClinicalTrials.gov

Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

October 31, 2021

Study Completion Date

November 6, 2021

Conditions
Neoplasms MalignantSurgeryVenous ThromboembolismProphylaxisAdherence, Medication
Interventions
DRUG

Apixaban 2.5 milligram

apixaban 2.5 milligram twice daily from discharge until postoperative day 29 +/- 1 day

Trial Locations (2)

L8L 2X2

Thrombosis Service, HHS-General Hospital, Hamilton

L8V 1C3

HHS-Juravinski Hospital, Hamilton

All Listed Sponsors
lead

McMaster University

OTHER

NCT04479579 - Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery | Biotech Hunter | Biotech Hunter